IFN-1 Bid crosstalk: foe or friend to stem cells

Under steady-state approximately 70% of the hematopoietic stem and progenitor cells (HSPC) in the bone marrow are quiescent, with low metabolic activity fueled by glycolytic metabolites (1). However, in response to exogenous demands such as cell loss or damage, or infection, they become highly proliferative and can efficiently and quickly expand or reconstitute the blood and immune systems (2,3).